Challenges in management of refractory pain and sedation in infants

Alexandra Oschman1, Karishma Rao2,3

  • 1Department of Pharmacy, Children's Mercy Hospital, Kansas City, MO, United States.

Frontiers in Pharmacology
|January 18, 2024
PubMed

Insights

Managing pain and sedation in medically complex preterm infants in the neonatal intensive care unit (NICU) is challenging. This review explores refractory pain, sedation management, and associated clinical challenges in these vulnerable infants.

Area of Science:

  • Neonatology
  • Pediatric Critical Care
  • Pharmacology

Background:

  • Improving survival rates in preterm infants has led to an increase in medically complex infants requiring prolonged neonatal intensive care unit (NICU) stays.
  • Effective management of pain and sedation in these chronic NICU patients remains a significant clinical challenge despite advances in neonatal care.

Purpose of the Study:

  • To summarize the current literature on the diagnosis and management of refractory pain and sedation in chronic NICU patients.
  • To highlight the challenges clinicians face when managing pain and sedation in this complex pediatric population.

Main Methods:

  • Comprehensive literature review of existing studies on pain and sedation management in neonatal and infant care.
  • Analysis of challenges including the development of appropriate assessment scales and clinician unfamiliarity with pediatric disease states and pharmacotherapy.
  • Exploration of potential roles for opioid-induced hyperalgesia (OIH) and delirium in refractory cases.

Main Results:

  • Development of validated pain, sedation, and withdrawal scales is needed for this population.
  • Limited data exists on the safety and efficacy of drug therapies like gabapentin, ketamine, and risperidone in infants.
  • Opioid-induced hyperalgesia (OIH) and delirium are often overlooked but may contribute to refractory pain and sedation issues.

Conclusions:

  • Managing refractory pain and sedation in chronic NICU infants presents multifaceted challenges.
  • Further research is crucial to establish evidence-based guidelines for the safe and effective use of pharmacotherapy in this vulnerable population.
  • Addressing OIH and delirium should be considered in the comprehensive care of these complex infants.

Related Concept Videos

Parenteral Anesthetics: Overview01:24

Parenteral Anesthetics: Overview

Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
128
Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
625
Stages of General Anesthesia01:22

Stages of General Anesthesia

Various sedation levels offer significant advantages in facilitating procedural interventions for patients undergoing medical or invasive surgical procedures. These levels span from anxiolysis to general anesthesia, providing a spectrum of sedative effects to cater to specific patient needs. Anxiolysis reduces anxiety and is achieved through minimal sedation, enabling patients to remain awake and responsive while feeling more at ease during the procedure. This level can benefit minor...
449
CNS Depressants: Barbiturates and Benzodiazepines01:14

CNS Depressants: Barbiturates and Benzodiazepines

CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
271
Sedatives and Hypnotics: Overview01:23

Sedatives and Hypnotics: Overview

Sedatives are drugs that alleviate anxiety, while hypnotics induce sleep. Both classes of medication suppress neuronal activity, leading to a calming effect for sedatives and facilitating sleep for hypnotics.
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
386
Sedatives and Hypnotics Drugs: Barbiturates01:20

Sedatives and Hypnotics Drugs: Barbiturates

Sedatives and hypnotics encompass a drug class that acts on the central nervous system (CNS) to alleviate anxiety, promote relaxation and induce sleep.These drugs function by amplifying the actions of the neurotransmitter γ-aminobutyric acid (GABA), resulting in reduced neuronal activity. Barbiturates, a subset of sedatives and hypnotics first synthesized in the late 1800s, are categorized into ultra-short, short, intermediate, and long-acting groups based on their duration of effect. A...
284